News and Press Releases
Novartis Kisqali shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
Invasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node-negative disease Results remain consistent across secondary endpoints, including...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 16, 2024
Closed Loop Medicine appoints Luba Greenwood as Chair of the Board of Directors
Appointment of notable investor and executive in healthcare and tech to support leadership team in preparation for commercial milestones 11 Sep 2024 -- London, UK -- Closed Loop Medicine Ltd.,...
Category: Biotechnology, Other, Pharmaceutical
Posted: September 11, 2024
Babraham Research Campus Cambridge CB22 3AT United Kingdom
EORTC Extends Medidata Partnership to Help Power New Phased of Oncology Research
Medidata technology deployed to increase access to and transform the patient experience for cancer trials 11 September 2024 -- London, UK -- Medidata, a Dassault Systèmes brand and leading provider...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 11, 2024
AI can detect lung nodules that could lead to lung cancer nearly 3 years before symptoms and actual diagnosis, study finds
Evidence presented at 2024 World Conference on Lung Cancer highlights chest X-ray AI’s potential to detect lung nodules early and expedite patient care 10 September 2024 -- New York, US...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: September 10, 2024
C/O RODl & Partner Legal Limited, 170 Edmund Street, Birmingham, United Kingdom B3 2HB 74909
PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes
Investment to enable progression of pipeline of novel degrader assets through pre-clinical development and support further development of GlueSEEKER platform Led by Parkwalk Advisors alongside existing investors BGF, Dr Jonathan...
Category: Drug Discovery, Other, Pharmaceutical
Posted: September 10, 2024
PhoreMost Ltd, Building B580, Room 2011, Babraham Research Campus, Babraham, Cambridge, CB22 3AT, United Kingdom
Epsilogen completes £12.5 million Series B financing expansion
Expansion brings total Series B funds raised to £43.25 million Proceeds to support the delivery of clinical Proof of Concept for MOv18 IgE 9 September 2024 -- London, UK --...
Category: Drug Discovery, Other, Pharmaceutical
Posted: September 9, 2024
European Commission Approves Astellas’ PADCEVTM (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer
First regimen approved in advanced urothelial cancer to demonstrate superiority to platinum-containing chemotherapy, the standard of care for nearly 40 years European Marketing Authorization based on positive overall survival and...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: August 28, 2024
European Commission approves RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer after failure of prior therapy
Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, have until now faced a poor prognosis and limited treatment options after disease progression on...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: August 27, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
European Commission approves BALVERSA®▼ (erdafitinib) for adult patients with unresectable or metastatic urothelial carcinoma
First pan FGFR kinase inhibitor to be approved in the European Economic Area, for adults with unresectable or metastatic urothelial carcinoma and susceptible FGFR3 alterations Approval based on THOR results,...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: August 23, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Cumulus Oncology and leadXpro Achieve Critical Milestone in GPR68 Drug Discovery Project
Small Molecules Identified for Therapeutic Intervention in Oncology and Inflammation Edinburgh, Scotland, and Villigen, Switzerland, 20 August 2024 – Cumulus Oncology, Europe’s first oncology-focused biotech creation company, announces that, in...
Category: Drug Discovery
Posted: August 22, 2024
Veridix AI, part of Emmes Group, Announces New Protocol Digitization Capabilities
Protocol digitization extracts structured data elements from unstructured text Automates database study builds, reducing build timelines by up to 30% Deployed within 40 study builds across Emmes CRO’s portfolio of...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: August 14, 2024
In a First for Pharma, Citeline SmartSolutions Take AI to New Levels, Optimizing Clinical Trial Planning and Site Selection
Protocol SmartDesign and Investigator SmartSelect bring treatments to patients faster by accelerating clinical trial development 13 August 2024 -- London, UK -- Citeline, a leader in intelligence solutions for the...
Category: Clinical Trials, Pharmaceutical
Posted: August 13, 2024
SSI Strategy and Metalmind Partner for Enterprise AI Solutions
23 July 2024 , New Jersey US, Kista, Sweden, – SSI Strategy LLC, a global leader in strategic consulting for life sciences, is pleased to announce a partnership with MPS...
Category: Biotechnology
Posted: July 30, 2024
CHMP recommends RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy
Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, currently face a poor prognosis and limited treatment options after disease progression on osimertinib1,2,3,4 ...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: July 26, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Deuterium Depletion Is the Key to Getting a Breakthrough in Cancer Therapy
Two review papers consolidate 30 years of research BUDAPEST, Hungary, July 25, 2024 / Biotech Newswire / -- HYD LLC for Cancer Research and Drug Development (HYD or the Company)...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: July 25, 2024
